Zhejiang Zhenyuan disclosed an earnings forecast, projecting a net loss attributable to the parent of 11 million to 16 million yuan in the first half of 2026, compared with a profit of 56.2637 million yuan in the same period last year. The net loss after deducting non-recurring items is expected to be 18 million to 23 million yuan, versus a profit of 30.1173 million yuan a year earlier. Basic earnings per share are estimated at negative 0.03 yuan to negative 0.05 yuan. The company attributed the performance change mainly to increased production and operating costs due to the high investment intensity of the Zhenyuan Biotechnology project, a decline in sales revenue and gross margin in traditional segments affected by pharmaceutical centralized procurement and intensifying industry competition, back taxes and late payment surcharges from a tax self-inspection, and higher financial expenses resulting from continued investment in project construction.
Zhejiang Zhenyuan Share Co LtdProjects net loss of 11-16 million yuan in H1 2026 vs profit of 56.26 million yuan last year, due to higher costs, lower sales, and tax charges.